Crossmark

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer

Crossref DOI link: https://doi.org/10.1186/s12885-018-4480-9

Published Online: 2018-05-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Guoxiu

Zhao, Jiuda

Song, Yan

Zhang, Wen

Sun, Yongkun

Zhou, Aiping

Huang, Jing

Du, Feng

Yang, Lin
License Information

Text and Data Mining valid from 2018-05-09
More Information

Article History

Received: 21 January 2018

Accepted: 3 May 2018

First Online: 9 May 2018

Ethics approval and consent to participate

: The Ethics Committee at Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College approved the study in accordance with the Declaration of Helsinki. All individuals gave written informed consent for participation in the study.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.